Lexaria Bioscience Corp. LXRP:US | LXX:CSE Drug Delivery Platform Innovator Corporate Presentation April 2020 LexariaBioscience.com 1
Disclaimer This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, evaluation of medical marijuana projects, alternative health projects or products, and cannabidiol-fortified products or services for participation and/or financing, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements including, without limitation, foreign exchange and other financial markets; changes of the interest rates on borrowings; whether or not the Company will be successful in executing its business plan in whole or in part; hedging activities; changes in commodity prices; changes in the marketing or capital project expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Lexaria Corp. operates. These and other risks and uncertainties are more fully described in our periodic reports and other disclosure documents filed by Lexaria Corp. from time to time with regulatory authorities available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov, and the reader is encouraged to review these documents. Planned dates stated herein are estimates only, based on best information available. Dates are not assured and are subject to revision without notice. The Company assumes no obligation, except as required by law, to update any forward-looking statement, whether as a result of new information, future events or otherwise. This presentation is not an offer to sell or a solicitation of an offer to buy securities of Lexaria Bioscience Corp. It is a short summary of certain information for introductory purposes only and is not to be relied upon for investment purposes. No statement within has been evaluated by the Food and Drug Administration, and no product or service is intended to diagnose, treat, cure or prevent any disease. 2 2
Lexaria Bioscience – Corporate Highlights ▪ Introducing Lexaria’s disruptive, patented DehydraTECH ™ : ▪ DehydraTECH changes how the body detects and absorbs lipophilic (i.e. fat soluble) beneficial compounds; ▪ Faster onset/offset and higher bioavailability in capsules, pills, foods, liquids, powders, etc.; ▪ Also tested in topical product formats with faster/higher bioabsorption rates; and ▪ 16 patents granted (>60 pending) covering method-of-use , composition-of-matter and medical treatment claims ▪ Lexaria is focused on commercializing its DehydraTECH technology mainly through strategic partners and licensees in the pharmaceutical and consumer products industries ▪ In-use in CPG products sold in the USA ▪ Human studies beginning for DehydraTECH application to antivirals (COVID-19 and other conditions) ▪ Applied R&D ongoing for new CPG/pharma offerings for Nicotine, NSAIDs (Ibuprofen, Aspirin) PDE5 Inhibitors (Viagra, Cialis) and other compounds 3
DehydraTECH ™ Patent Portfolio Method of Use, Composition of Matter and 16 ~60 Medical Treatment Claims • Multiple active ingredients Patent Applications Patents Granted • Multiple dosage forms – oral powders, foods, liquid 8 USA 10 emulsions, tablets, capsules, 8 Australia etc. Patent Families 4
DehydraTECH – Patented Technology Benefits Human Case Study – DehydraTECH Cannabidiol Absorption Main Benefits 90 mg DehydraTECH (D 90mg) vs. 100 mg Comparator (PTL101) D 90mg PTL101 - 100mg • Increases speed of bioabsorption Plasma concentration (ng/mL) 60 • Increases bioavailability (peak and total quantity of 50 absorption) • Reduces financial costs of drug treatments 40 • Improves potency at a given drug dose for greater 30 tolerability 20 • Increases brain absorption for CNS-targeted molecules 10 0 Additional Benefits 0 30 60 90 120 150 180 210 240 300 360 420 480 Time (min) Pharmacokinetic comparison of the ingestion of DehydraTECH TM 90mg (solid black solid circles) and PhytoTech Therapeutics’ • Improves palatability for oral drugs PTL101-100mg gelatin matrix capsules (dashed grey open squares) [Atsmon et al., Clinical Pharmacology in Drug Development 2018, 7(7) 751 – 758]. • Inexpensive to implement 5
How Does DehydraTECH ™ Work? Process: Results: 1) Combine API and Fatty Acid Oil Fatty acids are believed to block and shunt bound APIs away from bitter + taste receptors* Lipids enable gastric e.g.: Cannabidiol LCFA: sunflower oil protection and rapid 2) Apply to food/carrier particles passage** Small intestine quickly absorbs LCFAs into lymphatics e.g.: sorbitol, gum Arabic, etc. (bypassing first 3) Perform dehydration procedure pass liver effect) and Colloidal Complex MCFAs via the 4) Render as powder or liquid nanoemulsion liver*** suitable for use in desired final form factor *Coupland & Hayes (2014). Pharm Res. Nov 31(11); 2921-2939 API = Active Pharmaceutical Ingredient **Soehngen et al., (1998). Arthritis & Rheumatism. Vol 31, No. 3. LCFA = Long Chain Fatty Acid; MCFA = Medium Chain Fatty Acid 6 ***Iqbal & Hussain (2009). Am J Physiol Endocrinol Metab. Jun;296(6);E1184-94.
Pharma Programs Antiviral Therapies for COVID-19 and other Infectious Diseases Investor Presentation 7 7
COVID-19 Pandemic • Global pandemic spreading uncontrollably • No available preventative vaccine • Researchers world-wide are investigating antiviral and other therapies to potentially fight infection • Oral therapies needed for mass distribution • Many oral antiviral drugs are fat soluble and poorly absorbed orally, compromising potency and are exceptionally expensive , limiting access if hundreds of millions of doses are required. 8 8
Symptoms of COVID-19 9 9
DehydraTECH Antiviral Research Beginning • DehydraTECH is clinically proven to significantly increase bioavailability for fat soluble drugs • Initial study testing three antiviral medications • Pilot human study at a leading Canadian university planned • Objective is to increase potency for greater therapeutic response and tolerability and to lower cost • Research expected to lead to expanded safety and efficacy testing in coronavirus and other infectious disease animal models • Significant strategic partnering potential 10 10
Broad Drug Classes – COVID-19 & other Infectious Diseases COVID-19 HIV HSV Influenza EBV HEP CMV 11 11
Pharma Pipeline - DehydraTECH Drug Selection In vivo PK/PD/ Tox Phase I/II/III Clinicals Antiviral therapies Underway (COVID-19) and other infectious diseases CBD therapeutics Future Directions (potential utility against hypertension; seizure disorders and other indications) Research Expansion Nicotine NRT (Nicotine Replacement Therapies, NSAIDs and PDE5 Inhibitors NSAIDs, PDE5 inhibitors and other molecules) 12 12
Possible Pharma Expansion – DehydraTECH CBD for BP Reduction BP = Blood Pressure (expressed in millimetres of mercury) 13
Cannabinoid Products CPG Industry 14 14
Cannabinoid Products CPG Industry ▪ DehydraTECH is proven to cost-effectively enhance bioavailability, performance and palatability of cannabinoids such as CBD and THC in oral and topical product formats ▪ Lexaria has out-licensed DehydraTECH to companies in the sector for their product offerings ▪ Lexaria has additionally developed its own formulations for and the ability to service the growing CBD CPG products industry specifically ▪ The Food and Drug Administration has begun to engage Congress (announced March 2020) on rulemaking for CBD dietary supplement commercialization in the US ▪ Lexaria plans to grow revenues in the CBD CPG products industry through white label distribution and out-licensing of its DehydraTECH technology with strategic partners where regulations allow 15
Recommend
More recommend
